Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

March 27, 2015 8:37 PM ET


Company Overview of PhaseBio Pharmaceuticals, Inc.

Company Overview

PhaseBio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing drugs for endocrine and metabolic disorders, and cardiovascular disease. Its products include PB1023 for the treatment of hyperglycemia associated with type 2 diabetes, as well as with a potential for future use in the treatment of obesity; Insumera, a basal insulin ELP-fusion; and Vasomera, a vasoactive intestinal peptide agonist for acute and chronic heart failure and pulmonary arterial hypertension. PhaseBio Pharmaceuticals, Inc. was formerly known as Phase Bioscience, Inc. and it changed its name in November 2008. The company was founded in 2002 and is based in Malvern, Pennsylvania.

One Great Valley Parkway

Suite 30

Malvern, PA 19355

United States

Founded in 2002





Key Executives for PhaseBio Pharmaceuticals, Inc.

Chief Executive Officer
Age: 49
Executive Chairman
Co-Founder, Director and Member of Scientific Advisory Board
Chief Financial Officer
Age: 65
Senior Vice President of Clinical Development
Compensation as of Fiscal Year 2014.

PhaseBio Pharmaceuticals, Inc. Key Developments

PhaseBio Pharmaceuticals, Inc. Announces Management Appointments

PhaseBio Pharmaceuticals, Inc. announced the expansion of its leadership team. Clay Thorp, general partner at Hatteras Venture Partners, has been named Executive Chairman of the board of directors, Jonathan P. Mow has assumed the role of Chief Executive Officer, and James Ballance, Ph.D., has been appointed Vice President, Research and Scientific Affairs. Mr. Thorp is a general partner with Hatteras Venture Partners and brings many years of experience in starting and building biotechnology companies. Mr. Mow is a life sciences executive with more than 25 years of experience in biotech management. He previously served as Chief Business Officer of PhaseBio. Dr. Ballance has more than 25 years of experience in the biotech industry, within both small biotech and large pharma, specializing in early stage research, product development, cGMP manufacturing, technology transfer and the management of intellectual property.

PhaseBio Pharmaceuticals, Inc. Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014

PhaseBio Pharmaceuticals, Inc. Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 . Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States.

PhaseBio Expands Clinical Development of Vasomera

PhaseBio Pharmaceuticals, Inc. announced the successful completion of a Phase 1 trial of Vasomera(TM) (PB1046), the first once-weekly investigational, VPAC2 selective receptor agonist for the treatment of cardiopulmonary diseases. This multi-center, randomized, double-blind, placebo-controlled trial demonstrated the safety, tolerability and pharmacokinetic (PK)/pharmacodynamic (PD) response of single ascending subcutaneous (SC) doses of Vasomera in 40 patients. Trial results showed PD activity that was supportive of a once-weekly dosing regimen that could allow for chronic use in a home setting. In this Phase 1 trial, Vasomera was generally well tolerated with no clinically relevant cardiovascular safety signals identified. The Company plans to submit the full data set to an upcoming major medical meeting. Based on the clinical results of the Phase 1 trial evaluating SC Vasomera, PhaseBio has initiated a second Phase 1 trial to evaluate the safety, tolerability and PK/PD response of single ascending doses of short-term IV-infused Vasomera. IV administration of Vasomera would enable use in an acute hospital setting, with the goal of preserving or improving hemodynamic function in heart failure and reducing the incidence of re-hospitalization. The trial is expected to enroll up to 32 patients and will evaluate the acute impact of Vasomera on hemodynamic function using echocardiographic analyses. It will also provide support for the development of Vasomera for treatment of acute heart failure as well as pulmonary arterial hypertension (PAH). The trial is expected to complete in the third quarter of 2013.

Similar Private Companies By Industry

Company Name Region
Epeius Biotechnologies Corporation United States
BioFlage, Inc. United States
Lucena Medicines, Inc. United States
Select Therapeutics Inc. United States
GlycoFi, Inc. United States

Recent Private Companies Transactions

Private Placement
February 26, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PhaseBio Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at